ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SRRK / insiders
CGON (42) CRSP (35) IMVT (37) KOD (54) ⌘ Pro Terminal β†’

Scholar Rock Holding Corporation (SRRK) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$43.98 +2.49% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $44.09

Scholar Rock Holding Corporation (SRRK) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $5.23B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SRRK Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SRRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Scholar Rock Holding Corporation (NASDAQ: SRRK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $43.98 (+2.49% 1D, market cap $5.23B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SRRK ranks #432 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SRRK compare to CGON and CRSP in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRRK carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, CGON (CG Oncology Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B) and CRSP (CRISPR Therapeutics AG) posts a D- grade (35/100 RQD, P/E N/A, ROIC -30.6%, cap $4.83B). Among the 5-stock peer group, SRRK leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SRRK?
β–Ό

Per SRRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001727196), Scholar Rock Holding Corporation generated $1.08B in revenue (+52.6% YoY), -$378.0M in net income, and -$300.6M in free cash flow against $404.3M in total assets and $99.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $44.09 (+0.26%)🧬 Dilution Drag (+1.92% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (41/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510041
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D+
Cash (8)Whales (7)SEC (16)Macro (5)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
$65 Bull$41 Base$32 Bear
πŸ“¬ FREE SRRK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SRRK)Realized 20D OHLCV Swing Band: Β±7.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
πŸ” WHY SRRK SCORES 41/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (39% of score)

Altman Z-Score 13.67 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Cash Engine Quality+8/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
33
Grade E$40.64+3.2% Next Q
Q2 (-2Q)
36
Grade E$41.96+5.3% Next Q
Q3 (-1Q)
38
Grade E$44.18-0.5% Next Q
Current
41
Grade D-$43.98-7.2% Hist 90D Ξ±
Trajectory: E (33) β†’ D- (41)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SRRK Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SRRK currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($47.31) and Max Pain ($46.18) forces dealer call-delta covering toward $64.85.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRRKβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSRRK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

SRRK Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SRRK)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SRRK. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRRK)

  • βœ“Walkthrough of SRRK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SRRK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.68%πŸ“ HORIZONTAL RANGE
2026-11-04O $43.90H $43.98L $42.91C $43.98VOL 932.1K
RES: $66.71SUP: $36.83SMA50: $47.31SMA200: $48.17
$63.37$56.68$49.99$43.30$36.61RES $66.71SUP $36.83$43.982026-05-052026-06-222026-08-062026-09-222026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRRK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SRRK Butterfly Map β†’ + Track SRRK β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
24.7%/yr Implied 5Y Growth

vs. +52.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SRRK today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SRRK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SRRK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRRK)

Health Care Rank #432 of 1015 βš”οΈ CGON vs SRRK Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SRRK vs. CGON, CRSP, IMVT, KOD)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Scholar Rock Holding Corporation (SRRK) ranks #432 by composite RQD confidence (41/100, grade D-) and #154 by equity capitalization ($5.23B). Within this direct 5-issuer industry benchmark cohort, SRRK leads on earnings valuation at N/A trailing P/E, while CGON leads on capital efficiency and profitability with -20.8% ROIC and β€” gross margin. KOD currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with SRRK at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SRRK ACTIVE
Scholar Rock Holding Corporation
D- 41/100 β€” β€” -35.0% +2.49% $5.23B Benchmark Subject
CGON
CG Oncology Inc.
D- 42/100 β€” β€” -20.8% +3.39% $5.49B /cgon-vs-srrk β†’
CRSP
CRISPR Therapeutics AG
D- 35/100 β€” β€” -30.6% 0.00% $4.83B /crsp-vs-srrk β†’
IMVT
Immunovant Inc.
D- 37/100 β€” β€” -35.0% +2.22% $5.87B /imvt-vs-srrk β†’
KOD
Kodiak Sciences Inc
D+ 54/100 β€” β€” -35.0% +1.30% $6.14B /kod-vs-srrk β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001727196 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scholar Rock Holding Corporation (SRRK) reported GAAP revenue of $1.08B (+52.6% vs. FY2024 revenue of $705.8M , and +124.6% cumulative change since FY2023) , GAAP net income of -$378.0M, operating cash flow of -$300.0M, and free cash flow of -$300.6M (-49.5% YoY). On the balance sheet, SRRK closed FY2025 with $404.3M in total assets against $99.7M in total debt (Altman Z-Score: 13.67, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.08B -$378.0M -$300.0M -$300.6M $404.3M $99.7M
FY2024 (FY) 2024-12-31 $705.8M -$246.0M -$200.9M -$201.0M $474.9M $50.1M
FY2023 (FY) 2023-12-31 $479.6M -$166.0M -$145.2M -$145.2M $2.96B $692.5M

3. SRRK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Scholar Rock Holding Corporation (NASDAQ: SRRK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $43.98 (+2.49% 1D, market cap $5.23B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SRRK ranks #432 in composite RQD confidence.

How does SRRK compare to CGON and CRSP in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRRK carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, CGON (CG Oncology Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B) and CRSP (CRISPR Therapeutics AG) posts a D- grade (35/100 RQD, P/E N/A, ROIC -30.6%, cap $4.83B). Among the 5-stock peer group, SRRK leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SRRK?

Per SRRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001727196), Scholar Rock Holding Corporation generated $1.08B in revenue (+52.6% YoY), -$378.0M in net income, and -$300.6M in free cash flow against $404.3M in total assets and $99.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SRRK trading relative to its 50-day, 200-day, and 52-week technical levels?

SRRK last traded at $43.98 (+2.49% on volume of 676,854 shares), positioning the stock -7.04% below its 50-day simple moving average ($47.31) and -8.70% below its 200-day simple moving average ($48.17). Across its 52-week range of $27.07 to $61.76, SRRK sits at the 48.7% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±7.5% ($40.68 to $47.28).

Direct Sub-Reports: SRRK RQD Cockpit SRRK 12M Forecast SRRK Earnings & Move SRRK Dividends & DRIP SRRK Insiders & 13F SRRK Whale Options SRRK Profit Sankey SRRK News & Why
ROARABLE RATING BRIEF β€’ RQD 41/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

SRRK β€” Scholar Rock Holding Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Scholar Rock Holding Corporation (SRRK) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $43.98 (+2.49% 1D, market capitalization $5.23B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of -5.59%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (16/20): Incorporates a 1.02x equity beta, Altman Z-Score of 13.67, Piotroski F-Score of 5/9, and Debt/Equity of 0.41x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Scholar Rock Holding Corporation (SRRK) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile does not describe its products, customers, or revenue model. The reported revenue in the SEC financials is β€” for each period shown.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Scholar Rock Holding Corporation (SRRK) reported $1.08B in annual revenue (up from $705.8M in FY2024, +52.6% YoY) and -$378.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($479.6M revenue, -$166.0M net income) through FY2025, SRRK scaled operating cash flow to -$300.0M and free cash flow to -$300.6M, backed by $404.3M in total assets against $99.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 41/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -5.59% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $27.07 – $61.76 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.02x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), SRRK carries a macro regime beta of 1.02 and gross margin of β€”.

  • Key Question #1: Can SRRK sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.08B and free cash flow of -$300.6M, how will capital allocation balance growth reinvestment against $99.7M in total debt?
  • Key Question #3: How sensitive is SRRK's 32.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.02x)?

SRRK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scholar Rock Holding Corporation (SRRK) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SRRK Debate Forum (3) ↓
🟑 MARKET WIRE Yahoo Finance β€’ 27d ago
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass., October 08, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its

Read Full Source β†—
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SRRK Bull vs. Bear Conversation Board β€” What's Your Call at $43.98?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SRRK 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SRRK:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER β€’ Cross-Asset Macro Desk πŸ‚ BULLISH 🎯 Target: $53.12 (+21.0%)
πŸ“Œ Pinned Debate

The forensic balance sheet scores 16/20 with an Altman Z-Score of 13.67 and reported cash rising to $323.5M, giving the company a finan

The forensic balance sheet scores 16/20 with an Altman Z-Score of 13.67 and reported cash rising to $323.5M, giving the company a financial buffer despite operating losses.. When you look under the hood at SRRK, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $61.76. My 12M target is $53.12.

VolSurface_Trader πŸ‚ BULL

@MultipleCompression Shorting a 7/20 institutional whale-flow stock at $43.90 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $35.12 (-20.0%)
Spot @ $43.90

With ROIC at -35%, FCF of -$300.6M, and EPS (TTM) of -3.1, the company is consuming cash rather than generating it, and reported revenu

With ROIC at -35%, FCF of -$300.6M, and EPS (TTM) of -3.1, the company is consuming cash rather than generating it, and reported revenue is $0.0M.. Look at the math on SRRK: paying 32.0x forward P/E for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $38.63 before getting long.

LIVE TAPE